Skip to main content
Premium Trial:

Request an Annual Quote

Former Sequana CFO Joins Ventana Genetics

Premium

SALT LAKE CITY--Ventana Genetics here announced that M. Scott Salka is the biotech company's new CEO. Salka joined Ventana from genomics company Sequana Therapeutics, where he was vice president of operations and chief financial officer. At Sequana, Salka directed strategic planning and corporate development efforts, which included raising capital and structuring industry collaborations. He participated in Sequana's startup in 1993 and was instrumental in raising over $25 million in three rounds of private funding and nearly $50 million in two public equity financings, as well as negotiating four industry collaborations worth up to $250 million.

Filed under

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.